Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Glyxambi

    - PMLiVE

    Lilly announces new study data on Inluriyo in metastatic breast cancer

    The five-year survival rate for metastatic breast cancer is 30%

    - PMLiVE

    AstraZeneca’s Enhertu combination approved by FDA for HER2-positive breast cancer

    Around one in five breast cancer cases are HER2-positive

    - PMLiVE

    FDA approves first gene therapy for Wiskott-Aldrich syndrome

    Symptoms of the rare disease include bleeding, eczema and frequent infections

    - PMLiVE

    Lilly and Indiana University collaborate to expand clinical trial access

    The five-year agreement includes a focus on R&D for Alzheimer’s disease

    - PMLiVE

    Lilly announces plans for $6bn US manufacture facility

    The site is the third of four new US sites that Lilly has announced

    - PMLiVE

    FDA launches TEMPO digital health pilot

    Digital technologies can improve remote patient care for those with chronic diseases

    - PMLiVE

    Richard Pazdur, FDA’s drug evaluation chief, to leave FDA just weeks into new role

    Pazdur was previously head of the FDA’s Oncology Center of Excellence

    - PMLiVE

    AstraZeneca’s Imfinzi receives FDA approval for gastric and gastro-oesophageal cancers

    In 2022, nearly one million new patients were diagnosed with gastric cancer

    - PMLiVE

    Merck KGaA given FDA Fast Track designation for generalised myasthenia gravis drug

    Cladribine capsules could become the first ever oral treatment for gMG

    - PMLiVE

    AstraZeneca announces $2bn investment in US manufacturing

    The new and expanded facilities will support production of rare disease drug treatments

    - PMLiVE

    AstraZeneca reports positive results from rare disease trial

    HES is a group of rare disorders characterised by persistently elevated levels of white blood cells

    - PMLiVE

    Lilly and MeiraGTx partner in $475m ophthalmology deal

    The companies will develop and commercialise therapies for genetic conditions

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links